Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection
Top Cited Papers
- 24 November 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 53 (24), 8468-8484
- https://doi.org/10.1021/jm1004286
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Selectivity and therapeutic inhibition of kinases: to be or not to be?Nature Immunology, 2009
- Janus kinases in immune cell signalingImmunological Reviews, 2009
- The Year in Review – ATC 2002American Journal of Transplantation, 2003
- Cytokines and their role in lymphoid development, differentiation and homeostasisCurrent Opinion in Allergy and Clinical Immunology, 2002
- The amino terminus of JAK3 is necessary and sufficient for binding to the common γ chain and confers the ability to transmit interleukin 2-mediated signalsProceedings of the National Academy of Sciences of the United States of America, 1997
- Signaling via IL-2 and IL-4 in JAK3-Deficient Severe Combined Immunodeficiency Lymphocytes: JAK3-Dependent and Independent PathwaysImmunity, 1996
- Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiencyJournal of Leukocyte Biology, 1996
- Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)Nature, 1995
- Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling ProteinsScience, 1994
- Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humansCell, 1993